US STOCKS-Nasdaq and S&P 500 scale new peaks; Dow rallies

US STOCKS-Nasdaq and S&P 500 scale new peaks; Dow rallies
Added 12 hours ago
Summary: * Indexes: Dow +1.04%, S&P 500 +0.66%, Nasdaq +0.72% (Updates with afternoon trading details)
Sentiment: positive
4 minute read
1 people have read this
Cryptos: $AOA

Stocks making the biggest moves midday: Trade Desk, Eli Lily, Darden Restaurants and more

Stocks making the biggest moves midday: Trade Desk, Eli Lily, Darden Restaurants and more
Added 14 hours ago
Summary: These are the stocks posting the largest moves in midday trading.
Sentiment: positive
4 minute read
1 people have read this

Eli Lilly's Alzheimer's drug gets FDA Breakthrough Therapy designation

Eli Lilly's Alzheimer's drug gets FDA Breakthrough Therapy designation
Added 17 hours ago
Summary: Eli Lilly announced Thursday that it had received the FDA’s Breakthrough Therapy designation for donanemab, an investigational antibody therapy for Alzheimer’s disease.
Sentiment: positive
5 minute read
1 people have read this
Stocks: $BIIB

Nasdaq, S&P 500 scale new peak as jobs recovery gains traction

Nasdaq, S&P 500 scale new peak as jobs recovery gains traction
Added 18 hours ago
Summary: The Nasdaq and the S&P 500 indexes hit all-time highs on Thursday, boosted by shares of Tesla and other top-shelf technology firmsas data showing fewer weekly jobless claims bolstered views of a steady recovery in the labor market.
Sentiment: positive
5 minute read
1 people have read this

Doctors unsure on recommending new Alzheimer’s treatment

Doctors unsure on recommending new Alzheimer’s treatment
Added 19 hours ago
Summary: juststock/iStock(NEW YORK) -- This month, the Food and Drug Administration approved a new treatment for Alzheimer’s disease -- the first in nearly 20 years. But the decision was not without controversy, with doctors split on how they feel about the tre...
Sentiment: positive
10 minute read
1 people have read this
Stocks: $BIIB$DNOW

Stock Market News Live: Futures Point to Nasdaq Extending Its Run of Records - WSJ.com

Stock Market News Live: Futures Point to Nasdaq Extending Its Run of Records - WSJ.com
Added 21 hours ago
Summary: U.S. stock futures are gaining after markets ended Wednesday mixed with the Nasdaq hitting its 16th record close of the year and the Dow and S&P 500 falling slightly. Durable goods orders and jobless figures are due at 8:30 a.m. ET.
Sentiment: positive
1 minute read
1 people have read this
Cryptos: $RISE$RSV

Eisai's drug for Alzheimer's with Biogen gets breakthrough status in U.S.

Eisai's drug for Alzheimer's with Biogen gets breakthrough status in U.S.
Added a day ago
Summary: Japanese company Eisai Co (4523.T) and partner Biogen Inc (BIIB.O) said on Wednesday the U.S. Food and Drug Administration had granted breakthrough therapy designation to their experimental therapy, lecanemab, for patients with early Alzheimer's.
Sentiment: positive
2 minute read
1 people have read this
Stocks: $BIIB

FTSE 100 closes at session low, dropping back with US blue chips; oil prices hold firm

FTSE 100 closes at session low, dropping back with US blue chips; oil prices hold firm
Added a day ago
Summary: At the close, the UK blue-chip index was 15.95 points weaker at 7,074.06, the session low and well below the day’s peak of 7,12940
Sentiment: negative
3 minute read
1 people have read this
Cryptos: $BTC$RSV

FTSE 100 closes at session low, dropping back with US blue chips; oil prices hold firm

FTSE 100 closes at session low, dropping back with US blue chips; oil prices hold firm
Added 2 days ago
Summary: At the close, the UK blue-chip index was 15.95 points weaker at 7,074.06, the session low and well below the day’s peak of 7,12940
Sentiment: negative
3 minute read
2 people have read this
Cryptos: $BTC$RSV

FTSE 100 closes at session low, dropping back with US blue chips; oil prices hold firm

FTSE 100 closes at session low, dropping back with US blue chips; oil prices hold firm
Added 2 days ago
Summary: At the close, the UK blue-chip index was 15.95 points weaker at 7,074.06, the session low and well below the day’s peak of 7,12940
Sentiment: negative
3 minute read
1 people have read this
Cryptos: $BTC$RSV

Opinion | Why There’s New Hope for Alzheimer’s Patients

Opinion | Why There’s New Hope for Alzheimer’s Patients
Added 2 days ago
Summary: Biogen’s aducanumab isn’t a cure, but the trials were promising—and other therapies are in the works.
4 minute read
1 people have read this
Stocks: $BIIB$DNOW

Biogen now says it plans to complete 'confirmatory' study for Alzheimer's drug earlier than required

Biogen now says it plans to complete 'confirmatory' study for Alzheimer's drug earlier than required
Added 2 days ago
Summary: Shares of Biogen Inc. undefined were up 0.8% in premarket trading on Wednesday after the company and Eisai Inc. said they plan to speed up the completion of...
Sentiment: positive
2 minute read
1 people have read this
Stocks: $BIIB$DNOW

Internal Documents Reveal FDA Clash Over Alzheimer’s Therapy - BNN Bloomberg

Internal Documents Reveal FDA Clash Over Alzheimer’s Therapy - BNN Bloomberg
Added 2 days ago
Summary: Statisticians at the Food and Drug Administration who had a thorough look at the clinical-trial data didn’t support approval of Biogen Inc.’s Alzheimer’s therapy, internal documents released by the agency show.
Sentiment: positive
9 minute read
1 people have read this
Stocks: $BIIB

Documents reveal the FDA’s unprecedented path to approving Aduhelm

Documents reveal the FDA’s unprecedented path to approving Aduhelm
Added 2 days ago
Summary: Newly disclosed FDA documents reveal the agency’s unprecedented path to approving Aduhelm under accelerated approval.
Sentiment: positive
14 minute read
1 people have read this
Stocks: $BIIB

The FDA approved a controversial, $56,000-a-year Alzheimer's drug despite opposition inside the agency, internal memos show

The FDA approved a controversial, $56,000-a-year Alzheimer's drug despite opposition inside the agency, internal memos show
Added 2 days ago
Summary: The director of the FDA's biostatistics office said there wasn't enough evidence to approve Aduhelm, the first new Alzheimer's treatment in decades.
Sentiment: positive
5 minute read
1 people have read this

New Alzheimer’s Drug Could Cost the Government as Much as It Spends on NASA

New Alzheimer’s Drug Could Cost the Government as Much as It Spends on NASA
Added 3 days ago
Summary: The Alzheimer’s treatment will cost $56,000 per patient, and millions may use it. The result: “crazy numbers” for Medicare.
Sentiment: positive
3 minute read
1 people have read this
Cryptos: $UTED

Many Alzheimer’s Experts Say Use of Aduhelm Should Be Sharply Limited

Many Alzheimer’s Experts Say Use of Aduhelm Should Be Sharply Limited
Added 3 days ago
Summary: Even those who supported the F.D.A.’s approval of the controversial new drug said authorizing it for anyone with Alzheimer’s disease was much too broad.
Sentiment: positive
4 minute read
1 people have read this
Stocks: $BIIB

The 20 fastest-growing, highest-paying biotechs

The 20 fastest-growing, highest-paying biotechs
Added 4 days ago
Summary: These are Insider's biggest healthcare stories for June 21.
1 people have read this
Stocks: $BIIB$HUM
Cryptos: $DELTA

How a single new Alzheimer’s drug could blow up the federal budget

How a single new Alzheimer’s drug could blow up the federal budget
Added 5 days ago
Summary: A new medicine could cost taxpayers hundreds of billions of dollars. Will Washington crack down on drug prices in response?
Sentiment: positive
12 minute read
1 people have read this
Stocks: $BIIB

Trucker who drove into George Floyd protest may have charges dropped

Trucker who drove into George Floyd protest may have charges dropped
Added 6 days ago
Summary: The truck driver who drove through a large crowd protesting George Floyd's death last year will have his criminal charges dropped if he is law-abiding for...
Sentiment: negative
2 minute read
1 people have read this
Cryptos: $DAILY

Dow Jones Dives As Stocks Tumble In Quadruple Witching Trade; Adobe Leaps On Earnings; Lennar, Biogen Upgraded

Dow Jones Dives As Stocks Tumble In Quadruple Witching Trade; Adobe Leaps On Earnings; Lennar, Biogen Upgraded
Added 7 days ago
Summary: Earnings news boosted Adobe, Goldman Sachs broke technical support on the Dow Jones, and stocks fell into a quadruple witching session.
Sentiment: positive
9 minute read
1 people have read this
Cryptos: $BTC$RSV

Stocks making the biggest moves in the premarket: Adobe, Smith & Wesson, Orphazyme & more

Stocks making the biggest moves in the premarket: Adobe, Smith & Wesson, Orphazyme & more
Added 7 days ago
Summary: The stocks making the biggest moves in premarket trading include Adobe, Smith & Wesson, Orphazyme, and more.
Sentiment: negative
5 minute read
1 people have read this
Cryptos: $UTED$DELTA

Manchin Wants Biden To Oust FDA Chief Over Controversial Alzheimer’s Drug Approval

Manchin Wants Biden To Oust FDA Chief Over Controversial Alzheimer’s Drug Approval
Added 7 days ago
Summary: Sen. Joe Manchin says the FDA needs new leadership, after it signed off on an Alzheimer’s drug that most members of its own advisory panel questioned.
Sentiment: positive
5 minute read
1 people have read this
Stocks: $BIIB$TWTR

Looking for hedges against inflation? Try Apple, Nike, Verizon and stocks with this in common, strategists say

Looking for hedges against inflation? Try Apple, Nike, Verizon and stocks with this in common, strategists say
Added 8 days ago
Summary: Stocks are set for a poor performance on Thursday, as markets absorb the Federal Reserve’s indication that interest rate increases are coming sooner than...
Sentiment: positive
10 minute read
1 people have read this

First patient receives controversial Biogen Alzheimer's drug

First patient receives controversial Biogen Alzheimer's drug
Added 8 days ago
Summary: A U.S. hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer's drug from Biogen Inc (BIIB.O) before Medicare had even said what it will pay for - and with some doctors upset by its approval last week.
Sentiment: positive
7 minute read
1 people have read this
Stocks: $BIIB$TISI
Cryptos: $UTED

Biogen's debated Alzheimer's drug given to first patient

Biogen's debated Alzheimer's drug given to first patient
Added 8 days ago
Summary: A Rhode Island man became the first patient worldwide to receive Biogen’s hotly debated Alzheimer’s drug outside of a clinical trial on Wednesday, a hospital spokesperson confirmed to Fox News.
Sentiment: positive
2 minute read
1 people have read this
Stocks: $BIIB$DNOW

First patient receives controversial Biogen Alzheimer’s drug

First patient receives controversial Biogen Alzheimer’s drug
Added 9 days ago
Summary: A US hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer’s drug from Biogen.
Sentiment: positive
2 minute read
1 people have read this
Stocks: $BIIB$TISI
Cryptos: $UTED

Dow Jones Today Lags In Mixed Trade Ahead Of Fed; Oracle Dives On Guidance; Cleveland Cliffs, Steelmakers Dive

Dow Jones Today Lags In Mixed Trade Ahead Of Fed; Oracle Dives On Guidance; Cleveland Cliffs, Steelmakers Dive
Added 9 days ago
Summary: Oracle dived on earnings and Caterpillar dragged on the Dow Jones today, as stocks awaited policy news from the Federal Reserve.
Sentiment: positive
11 minute read
2 people have read this

Why tech platforms are using blockchain technology | Nairametrics

Why tech platforms are using blockchain technology | Nairametrics
Added 9 days ago
Summary: Blockchain technology has rapidly evolved since 2008. What began as the building block for Bitcoin is now spreading across various industries.
Sentiment: positive
6 minute read
2 people have read this
Cryptos: $BTC$RMT

Futures hold steady with Fed meeting in focus

Futures hold steady with Fed meeting in focus
Added 9 days ago
Summary: Futures tied to the S&P 500 and the Nasdaq held near record highs on Tuesday as investors looked for comments from the Federal Reserve about whether a recent jump in inflation would prompt a sooner-than-expected tapering in monetary policy.
Sentiment: positive
3 minute read
1 people have read this
Cryptos: $RSV

Biotechs Decline After Sage-Biogen Depression Drug Misses Mark

Biotechs Decline After Sage-Biogen Depression Drug Misses Mark
Added 10 days ago
Summary: For the second time in less than a week the biotech sector got disappointing news after a closely-watched study from Sage Therapeutics Inc. and Biogen Inc. failed to ignite a much-needed rally.
Sentiment: positive
3 minute read
1 people have read this
Cryptos: $ARK

For Those Facing Alzheimer's, A Controversial Drug Offers Hope

For Those Facing Alzheimer's, A Controversial Drug Offers Hope
Added 10 days ago
Summary: A plaque-busting Alzheimer's drug called Aduhelm has yet to prove it can preserve memory and thinking. Even so, its approval by the Food and Drug Administration is making some patients opitimistic.
1 people have read this
Cryptos: $PEARL

Biogen says experimental drug for rare retinal disease fails in late-stage clinical trial

Biogen says experimental drug for rare retinal disease fails in late-stage clinical trial
Added 10 days ago
Summary: Shares of Biogen Inc. undefined were down 0.3% in premarket trading on Tuesday, the day after the company said an experimental gene therapy for choroideremia...
Sentiment: negative
2 minute read
1 people have read this
Stocks: $BIIB$SAGE

US STOCKS-S&P 500, Nasdaq to open near record highs with Fed meeting in focus

US STOCKS-S&P 500, Nasdaq to open near record highs with Fed meeting in focus
Added 10 days ago
Summary: * Futures: Dow and S&P up 0.1%, Nasdaq rises 0.1% (Adds comment, updates prices)
Sentiment: positive
4 minute read
1 people have read this
Cryptos: $RSV

Wall Street dips after S&P 500 hits record high; Fed meeting in focus

Wall Street dips after S&P 500 hits record high; Fed meeting in focus
Added 10 days ago
Summary: Wall Street dips after S&P 500 hits record high; Fed meeting in focus
Sentiment: positive
4 minute read
1 people have read this
Cryptos: $FSN$RSV

Futures, Rates Calm Ahead Of FOMC As Copper Crumbles

Futures, Rates Calm Ahead Of FOMC As Copper Crumbles
Added 10 days ago
Summary: ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
Sentiment: positive
35 minute read
1 people have read this

Futures hold steady with Fed meeting in focus

Futures hold steady with Fed meeting in focus
Added 10 days ago
Summary: Futures tied to the S&P 500 and the Nasdaq held near record highs on Tuesday as investors looked for comments from the Federal Reserve about whether a recent jump in inflation would prompt a sooner-than-expected tapering in monetary policy.
Sentiment: positive
3 minute read
1 people have read this
Cryptos: $RSV

Sage, Biogen MDD treatment meets primary endpoint

Sage, Biogen MDD treatment meets primary endpoint
Added 10 days ago
Summary: Sage Therapeutics Inc. undefined and partner Biogen Inc. undefined said a Phase 3 study of their major depressive disorder (MDD) treatment met its primary...
Sentiment: positive
2 minute read
1 people have read this
Stocks: $BIIB$SAGE

U.S. Futures Largely Flat; Fed Starts Meeting, PPI Data Due

U.S. Futures Largely Flat; Fed Starts Meeting, PPI Data Due
Added 10 days ago
Summary: U.S. Futures Largely Flat; Fed Starts Meeting, PPI Data Due
Sentiment: positive
4 minute read
1 people have read this
Cryptos: $FSN$RSV$UTED

Biogen Falls Premarket As Eye Disease Treatment Fails Test

Biogen Falls Premarket As Eye Disease Treatment Fails Test
Added 10 days ago
Summary: Biogen Falls Premarket As Eye Disease Treatment Fails Test
Sentiment: negative
2 minute read
1 people have read this
Stocks: $BIIB$NDAQ
Cryptos: $FSN

Japanese shares track Nasdaq higher, drug makers shine

Japanese shares track Nasdaq higher, drug makers shine
Added 10 days ago
Summary: Japanese shares closed higher on Tuesday, buoyed by technology and growth-oriented stocks following a strong finish on the Nasdaq overnight, while drug makers extended their gains.
Sentiment: positive
3 minute read
1 people have read this
Cryptos: $RSV

2 Large Cap Biotech Stocks Up More Than 25% in the Last Month

2 Large Cap Biotech Stocks Up More Than 25% in the Last Month
Added 10 days ago
Summary: 2 Large Cap Biotech Stocks Up More Than 25% in the Last Month
Sentiment: positive
2 minute read
1 people have read this
Stocks: $BIIB$NDAQ
Cryptos: $FSN$CAP

How Private Equity Conquered the Tax Code

How Private Equity Conquered the Tax Code
Added 11 days ago
Summary: How a powerful industry conquered the U.S. tax system.
Sentiment: positive
3 minute read
1 people have read this
Cryptos: $BTC

Novavax, AMC, Orphazyme, Corsair Gaming: What to Watch When the Stock Market Opens Today

Novavax, AMC, Orphazyme, Corsair Gaming: What to Watch When the Stock Market Opens Today
Added 11 days ago
Summary: Futures suggest the S&P 500 could hit another record.
Sentiment: positive
1 minute read
1 people have read this
Cryptos: $BTC$MEME$AOA

WSJ Opinion: Hits and Misses of the Week

Added 12 days ago
Summary:

Journal Editorial Report: The week's best and worst from Kim Strassel, Mary O'Grady, Joe Sternberg and Dan Henninger. Image: Invision/Biogen/AP Composite: Mark Kelly

1 people have read this
Stocks: $BIIB

How the new Alzheimer’s drug works—and why the FDA is under fire for approving it

How the new Alzheimer’s drug works—and why the FDA is under fire for approving it
Added 12 days ago
Summary: The first drug approved for the disease in 18 years, Aduhelm shows only scant benefit in clinical trials, and experts debate whether it even has the right biological target.
Sentiment: positive
14 minute read
1 people have read this
Stocks: $BIIB$DNOW
Cryptos: $DMD

Invesco Launches 2 "Zero Fee" ETFs As Sponsors Compete To Offer Cheapest Funds

Invesco Launches 2 "Zero Fee" ETFs As Sponsors Compete To Offer Cheapest Funds
Added 12 days ago
Summary: ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
Sentiment: positive
2 minute read
2 people have read this

Biotech Rally Sparked by Alzheimer’s Drug Has Staying Power

Biotech Rally Sparked by Alzheimer’s Drug Has Staying Power
Added 12 days ago
Summary: Controversy surrounding Biogen’s Aduhelm could ignite political firestorm over high drug prices, but investors should look past any D.C. drama.
Sentiment: positive
3 minute read
1 people have read this

2 Unstoppable Growth Stocks That Can Make You Richer Than Dogecoin

2 Unstoppable Growth Stocks That Can Make You Richer Than Dogecoin
Added 12 days ago
Summary: These two companies are less volatile than the cryptocurrency, and they offer better long-term prospects, too.
Sentiment: positive
9 minute read
2 people have read this

Fred DeLuca ran Subway like a titan, sleeping with franchisees' wives, micromanaging, and penny-pinching. Insiders say he set it up for failure.

Fred DeLuca ran Subway like a titan, sleeping with franchisees' wives, micromanaging, and penny-pinching. Insiders say he set it up for failure.
Added 12 days ago
Summary: He maintained a tight grip on the company operations and surrounded himself with employees who loved and feared him.
Sentiment: positive
7 minute read
1 people have read this

F.D.A. Still Lacks a Permanent Commissioner

F.D.A. Still Lacks a Permanent Commissioner
Added 13 days ago
Summary: With the pandemic easing, the federal agency’s long-term agenda for drug approvals or new issues is languishing without a permanent commissioner.
Sentiment: negative
4 minute read
1 people have read this
Cryptos: $UTED$MAG

Pharma is winning the big business popularity contest

Pharma is winning the big business popularity contest
Added 13 days ago
Summary: COVID-19 vaccines made pharma more popular, while tech’s ratings took a nosedive over the past year. Also this week, research showed why the Alpha coronavirus variant spreads so quickly.
Sentiment: positive
7 minute read
1 people have read this
Cryptos: $UTED

Biogen Alzheimer’s drug and the battle over dementia treatment of the future

Biogen Alzheimer’s drug and the battle over dementia treatment of the future
Added 13 days ago
Summary: Biogen Alzheimer's drug Aduhelm is the first new treatment for dementia approved by the FDA in decades, and it's started a war over the brain drug pipeline.
Sentiment: positive
18 minute read
1 people have read this

Here's How Insurers May Cover That Expensive New Alzheimer's Drug

Here's How Insurers May Cover That Expensive New Alzheimer's Drug
Added 13 days ago
Summary: Health care experts expect broad coverage of the drug, but what that means for patients will vary widely depending on their insurance plan.
Sentiment: positive
7 minute read
1 people have read this
Stocks: $BIIB

Three experts resign as FDA advisors over approval of Alzheimer’s drug

Three experts resign as FDA advisors over approval of Alzheimer’s drug
Added 13 days ago
Summary: One former advisor accused the FDA of presenting “slanted” questions to committee.
Sentiment: positive
7 minute read
2 people have read this
Stocks: $BIIB$DNOW

US STOCKS-Wall Street muted as eyes turn to next week's Fed meeting

US STOCKS-Wall Street muted as eyes turn to next week's Fed meeting
Added 13 days ago
Summary: * Indexes: Dow down 0.12%, S&P flat, Nasdaq up 0.13% (Updates to late afternoon, changes dateline, byline)
Sentiment: positive
5 minute read
1 people have read this
Cryptos: $RSV

Biotech Finds Market Love at Last as Meme Traders, FDA Converge

Biotech Finds Market Love at Last as Meme Traders, FDA Converge
Added 13 days ago
Summary: Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. Now investors are taking a second look at the sector.
Sentiment: positive
7 minute read
1 people have read this

Wall Street ekes out gains to close languid week

Wall Street ekes out gains to close languid week
Added 13 days ago
Summary: U.S. stocks closed modestly higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.
Sentiment: positive
5 minute read
1 people have read this
Cryptos: $RSV

US STOCKS-S&P ekes out gains to close languid week

US STOCKS-S&P ekes out gains to close languid week
Added 13 days ago
Summary: The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.
Sentiment: positive
4 minute read
1 people have read this
Cryptos: $RSV

Biogen stock heads for biggest weekly rally in more than 2 decades, UBS analyst targets more gains

Biogen stock heads for biggest weekly rally in more than 2 decades, UBS analyst targets more gains
Added 13 days ago
Summary: Shares of Biogen Inc. undefined dropped 4.1% in afternoon trading Friday, to pull back from a six-year high, but UBS analyst Colin Bristow seems room for...
Sentiment: positive
2 minute read
1 people have read this
Stocks: $BIIB

3 Experts Have Resigned From An FDA Committee Over Alzheimer's Drug Approval

3 Experts Have Resigned From An FDA Committee Over Alzheimer's Drug Approval
Added 14 days ago
Summary: In his resignation letter, Dr. Aaron Kesselheim calls it "probably the worst drug approval decision in recent U.S. history." An FDA official says the agency found the benefits outweighed the risks.
2 people have read this

US STOCKS-Wall Street flat with Fed meet in focus

US STOCKS-Wall Street flat with Fed meet in focus
Added 14 days ago
Summary: * Indexes: Dow down 0.17%, S&P flat, Nasdaq up 0.05% (Updates to midday)
Sentiment: positive
5 minute read
2 people have read this
Cryptos: $RSV

Stocks making the biggest moves midday: Chewy, Biogen, Snowflake and more

Stocks making the biggest moves midday: Chewy, Biogen, Snowflake and more
Added 14 days ago
Summary: These are the stocks posting the largest moves in midday trading.
Sentiment: positive
5 minute read
2 people have read this
Cryptos: $MAG

Wall Street flat with Fed meet in focus

Wall Street flat with Fed meet in focus
Added 14 days ago
Summary: U.S. stock indexeswere flat on Friday as focus turned to next week's Federal Reserve meeting, while technology and growth- exposed sectors gained after inflation data calmed fears over a long-term spike in consumer prices.
Sentiment: positive
5 minute read
3 people have read this
Cryptos: $RSV

The newest Alzheimer's drug is coming to Western New York. What you should know

The newest Alzheimer's drug is coming to Western New York. What you should know
Added 14 days ago
Summary: Aducanumab is the first FDA-approved drug proven to destroy amyloid plaque buildup in the brain, a telltale sign of Alzheimer’s.
Sentiment: positive
15 minute read
1 people have read this
Stocks: $BIIB$DNOW

New study suggests laughing gas may treat depression

New study suggests laughing gas may treat depression
Added 14 days ago
Summary: Nitrous oxide was shown to provide patients relief from their depression symptoms.
Sentiment: positive
4 minute read
2 people have read this

Dow Jones Today, Stocks And Bond Yields Edge Up; Vertex Dives On Trial Results; Can CAT Stock Rebound?

Dow Jones Today, Stocks And Bond Yields Edge Up; Vertex Dives On Trial Results; Can CAT Stock Rebound?
Added 14 days ago
Summary: Cleveland Cliffs and Dave & Buster's rallied, Caterpillar rose on the Dow Jones today, as stocks aimed to finish the week on a positive note.
Sentiment: positive
9 minute read
2 people have read this

Wall Street flat with Fed meet in focus

Wall Street flat with Fed meet in focus
Added 14 days ago
Summary: U.S. stock indexeswere flat on Friday as focus turned to next week's Federal Reserve meeting, while technology and growth- exposed sectors gained after inflation data calmed fears over a long-term spike in consumer prices.
Sentiment: positive
5 minute read
1 people have read this
Cryptos: $RSV

What a controversial drug approval could mean for future Alzheimer's treatments

What a controversial drug approval could mean for future Alzheimer's treatments
Added 14 days ago
Summary: These are Insider's biggest healthcare stories for the week ending June 11.
Sentiment: positive
4 minute read
1 people have read this

ANALYSIS | US FDA faces mounting criticism over Alzheimer's drug approval

ANALYSIS | US FDA faces mounting criticism over Alzheimer's drug approval
Added 14 days ago
Summary: In approving the first new Alzheimer's drug in nearly 20 years, the US Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.
Sentiment: positive
12 minute read
2 people have read this

The Drug That Could Break American Health Care

The Drug That Could Break American Health Care
Added 14 days ago
Summary: Aduhelm, the first new Alzheimer’s drug in 18 years, may not work. But states and Medicare may pay billions of dollars for it anyway.
Sentiment: positive
17 minute read
1 people have read this
Stocks: $BIIB$DNOW
Cryptos: $UTED

Analysis: U.S. FDA faces mounting criticism over Alzheimer's drug approval

Analysis: U.S. FDA faces mounting criticism over Alzheimer's drug approval
Added 14 days ago
Summary: Analysis: U.S. FDA faces mounting criticism over Alzheimer's drug approval
Sentiment: positive
10 minute read
1 people have read this
Cryptos: $FSN

Stocks making the biggest moves in the premarket: Snowflake, Vertex Pharmaceuticals, Chewy & more

Stocks making the biggest moves in the premarket: Snowflake, Vertex Pharmaceuticals, Chewy & more
Added 14 days ago
Summary: The stocks making the biggest moves in premarket trading include Snowflake, Vertex Pharmaceuticals, Chewy, and more.
Sentiment: positive
5 minute read
1 people have read this

Third member of FDA expert committee resigns over Alzheimer's decision

Third member of FDA expert committee resigns over Alzheimer's decision
Added 14 days ago
Summary: Kesselheim wrote that the approval of Biogen’s Aduhelm “was probably the worst drug approval decision in recent U.S. history.”
Sentiment: positive
6 minute read
1 people have read this
Stocks: $BIIB

Top Stories this AM: A tentative infrastructure deal is struck; a COVID outbreak at a maskless crypto conference; elf ears are in

Top Stories this AM: A tentative infrastructure deal is struck; a COVID outbreak at a maskless crypto conference; elf ears are in
Added 14 days ago
Summary: A bipartisan group of 10 senators announced they struck an early infrastructure deal on Thursday, but it won't include tax hikes, and only a fraction of it is new spending.
1 people have read this
Cryptos: $BTC

Top Stories this AM: A tentative infrastructure deal is struck; a COVID outbreak at a maskless crypto conference; elf ears are in

Top Stories this AM: A tentative infrastructure deal is struck; a COVID outbreak at a maskless crypto conference; elf ears are in
Added 14 days ago
Summary: A bipartisan group of 10 senators announced they struck an early infrastructure deal on Thursday, but it won't include tax hikes, and only a fraction of it is new spending.
1 people have read this
Cryptos: $BTC

Third member of US FDA advisory panel resigns over Alzheimer's drug approval

Third member of US FDA advisory panel resigns over Alzheimer's drug approval
Added 14 days ago
Summary: A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency's decision to approve Biogen Inc's Alzheimer's disease treatment despite the committee's recommendation against doing so.
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB

Medicare copays for new Alzheimer's drug could soar

Medicare copays for new Alzheimer's drug could soar
Added 14 days ago
Summary: The first new Alzheimer’s drug in nearly 20 years has received approval from the Food and Drug Administration.
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB

Japanese shares edge down as tech stocks weigh

Japanese shares edge down as tech stocks weigh
Added 14 days ago
Summary: Japanese shares inched down in seesaw trading on Friday as technology stocks pulled back from early gains, with investors remaining cautious about the pace of domestic economic recovery.
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB$NDAQ
Cryptos: $RSV$UTED

Third member of U.S. FDA advisory panel resigns over Alzheimer’s drug approval

Third member of U.S. FDA advisory panel resigns over Alzheimer’s drug approval
Added 14 days ago
Summary: A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency's decision to approve Biogen Inc's (BIIB.O) Alzheimer's disease treatment despite the committee's recommendation against doing so.
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB

A third member of a prestigious FDA panel has resigned over the approval of a controversial new Alzheimer's drug

A third member of a prestigious FDA panel has resigned over the approval of a controversial new Alzheimer's drug
Added 14 days ago
Summary: Dr. Aaron Kesselheim said the agency's decision to approve Biogen's new drug "was probably the worst drug approval decision in recent US history."
Sentiment: positive
5 minute read
1 people have read this
Stocks: $BIIB

Third member of FDA advisory panel resigns over Alzheimer's drug approval

Third member of FDA advisory panel resigns over Alzheimer's drug approval
Added 14 days ago
Summary: The resignations are in protest over the agency's decision to approve Biogen Inc's Alzheimer's treatment despite the committee's recommendation against doing so.
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB

Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually

Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually
Added 14 days ago
Summary: Some advisors to the Food and Drug Administration have quit over the drug which critics say has questionable benefits. The FDA said it can reduce clumps of plaque in the brain and may slow dementia.
Sentiment: positive
8 minute read
1 people have read this
Stocks: $BIIB

THIRD member of FDA advisory body resigns, calls Alzheimer drug approval ‘worst in recent US history’

THIRD member of FDA advisory body resigns, calls Alzheimer drug approval ‘worst in recent US history’
Added 14 days ago
Summary: Three scientists from a FDA advisory committee have resigned so far, after the US food and drug regulator rammed through an approval of a controversial drug to treat Alzheimer’s disease against their near-unanimous opposition.
1 people have read this
Stocks: $BIIB$TWTR

Third member of US FDA advisory panel resigns over Alzheimer's drug approval

Third member of US FDA advisory panel resigns over Alzheimer's drug approval
Added 14 days ago
Summary: A third member of a panel of outside advisers to the US Food and Drug Administration has resigned in protest over the agency's decision to approve ...
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB

Third member of U.S. FDA advisory panel resigns over Alzheimer's drug approval

Third member of U.S. FDA advisory panel resigns over Alzheimer's drug approval
Added 14 days ago
Summary: Third member of U.S. FDA advisory panel resigns over Alzheimer's drug approval
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB$NDAQ
Cryptos: $FSN

Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug

Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug
Added 14 days ago
Summary: A third member of a key FDA panel has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug, Aduhelm, CNBC has learned.
Sentiment: positive
6 minute read
1 people have read this
Stocks: $BIIB

Stocks making the biggest moves midday: RH, Signet Jewelers, Clover & more

Stocks making the biggest moves midday: RH, Signet Jewelers, Clover & more
Added 15 days ago
Summary: These are the stocks posting the largest moves in midday trading.
Sentiment: positive
4 minute read
1 people have read this
Stocks: $BIIB$NOW$RH
Cryptos: $MEME

Two members of FDA panel resign in protest over Alzheimer's drug approval

Two members of FDA panel resign in protest over Alzheimer's drug approval
Added 15 days ago
Summary: The 11-member committee voted nearly unanimously in November that Biogen's drug should not be approved, citing inconclusive evidence.
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB

Two members of U.S. FDA advisory panel resign over Alzheimer's drug approval

Two members of U.S. FDA advisory panel resign over Alzheimer's drug approval
Added 15 days ago
Summary: Two members of a panel of outside advisors to the U.S. Food and Drug Administration have resigned in protest at the agency's decision to approve Biogen Inc's (BIIB.O) Aduhelm for treatment of Alzheimer's disease despite the committee’s recommendation against doing so.
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB

FDA Approves First New Alzheimer’s Disease Drug in Nearly 20 Years | All About Arizona News

FDA Approves First New Alzheimer’s Disease Drug in Nearly 20 Years | All About Arizona News
Added 15 days ago
Summary: Monday, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the…
Sentiment: positive
8 minute read
2 people have read this
Stocks: $BIIB

Japan's Nikkei ends higher on economic rebound hopes; Eisai drags Topix

Japan's Nikkei ends higher on economic rebound hopes; Eisai drags Topix
Added 15 days ago
Summary: Japan's Nikkei index closed higher on Thursday, as shipping firms rose on prospects of more economic reopenings and drugmakers were boosted by reports of government support.
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB

Japanese shares rise, Eisai drops after 2 days of limit-up gains

Japanese shares rise, Eisai drops after 2 days of limit-up gains
Added 15 days ago
Summary: Japanese shares inched higher on Thursday, as the service sector gained on prospects of economic reopenings and drugmakers rose on reports of government support, though Eisai eased after a big jump following U.S. approval of its Alzheimer's disease drug.
Sentiment: positive
3 minute read
1 people have read this
Stocks: $BIIB

Dow Jones Slips; Meme-Mania Sends WWE Stock Flying As AMC Is Slammed; Microsoft Gains

Dow Jones Slips; Meme-Mania Sends WWE Stock Flying As AMC Is Slammed; Microsoft Gains
Added 16 days ago
Summary: The Dow Jones fell and the Nasdaq slipped. WWE stock flew above a buy point amid meme stock mania, even as AMC stock got pinned. Microsoft stock rose.
Sentiment: positive
6 minute read
2 people have read this

The Feds Hacked Ransomware Hackers

The Feds Hacked Ransomware Hackers
Added 16 days ago
Summary: The recovery of ransom paid by the Colonial Pipeline operator allays some worries about cryptocurrency — but worries others.
Sentiment: positive
3 minute read
2 people have read this

Biogen Stock To See Much Higher Levels After A 38% Rise Yesterday

Biogen Stock To See Much Higher Levels After A 38% Rise Yesterday
Added 16 days ago
Summary: We believe that the stock price of ​Biogen, a biotechnology company focused on treatments for neurological diseases, looks attractive at current levels of $396, despite it being up 38% from the levels of around $290 it was at yesterday morning. The sharp jump in BIIB stock can be attributed to the..
1 people have read this

A “disgraceful decision:” Researchers blast FDA for approving Alzheimer’s drug

A “disgraceful decision:” Researchers blast FDA for approving Alzheimer’s drug
Added 16 days ago
Summary: Even the FDA's own advisors and statisticians didn't think the drug should be approved.
Sentiment: positive
13 minute read
2 people have read this
Stocks: $BIIB$ROOT

Landmark Alzheimer's Drug Approval Confounds Research Community

Landmark Alzheimer's Drug Approval Confounds Research Community
Added 16 days ago
Summary: Many scientists say there is not enough evidence that Biogen’s aducanumab is an effective therapy for the disease
Sentiment: positive
15 minute read
1 people have read this
Cryptos: $UTED

Alzheimer Drug News: Biogen to start shipping Alzheimer's drug in about two weeks | World News - Times of India

Alzheimer Drug News: Biogen to start shipping Alzheimer's drug in about two weeks | World News - Times of India
Added 16 days ago
Summary: US News: Biogen Inc said on Tuesday it expects to begin shipping its newly approved Alzheimer's drug Aduhelm in about two weeks and that over 900 infusion cent.
1 people have read this
Stocks: $BIIB

Biogen is pricing aducanumab at $56,000 but it's worth less than $10,000

Biogen is pricing aducanumab at $56,000 but it's worth less than $10,000
Added 16 days ago
Summary: Biogen has set the price of its Alzheimer's treatment Aduhelm at $56,000 a year. It is worth a lot less
Sentiment: positive
8 minute read
1 people have read this
Stocks: $BIIB$DNOW